Search Results (2,794)

Background/Objectives: Myocardial ischemia–reperfusion injury (MIRI) remains an ever-growing threat in the field of cardiology, as it has become a major risk factor for unfavorable outcomes following reperfusion therapies. Oxidative stress and inflammation remain the key pathophysiological mechanisms underlying MIRI, and the presently available treatments fail to prevent this process effectively. This systematic review aimed to summarize and critically assess the latest preclinical research (2020–2026) on nanocarrier-based interventions targeting oxidative stress in MIRI, highlighting the potential of the new nanostructures in cardioprotection. Methods: A total of 24 studies meeting the PRISMA criteria have been found through a literature search of PubMed, Embase, and Web of Science databases published between 2020 and 2026. The studies eligible for inclusion had focused on the efficacy of nanocarrier-based interventions in preclinical studies of MIRI. Results: Of the 24 included studies, all investigated nanocarrier-based interventions in preclinical models of MIRI. In vitro, ex vivo, and in vivo models were diverse, with most studies being a combination of both in vitro and in vivo models. Commonly studied were lipid-based nanocarriers, polymeric nanoparticles, and biomimetic nanocarriers. Across studies assessed for this review, treatments with nanocarriers were seen to suppress inflammatory and oxidative stress pathways, with a few studies showing a suppression of cardiomyocyte apoptosis. Cardiac function was restored as determined by echocardiography analyses or ex vivo models of the myocardium, thus validating that the nanocarrier-mediated therapies are effective against MIRI. Conclusions: The analyzed preclinical studies indicate that the described therapies could provide a promising basis for future clinical trials in the treatment of MIRI, provided their safety and efficacy are confirmed in clinical trials. Full article

In the present work, the elastic modulus of several types of polymer nanocomposites has been analyzed with a semiempirical model which takes into consideration agglomerate formation and their impact on the nanocomposites’ mechanical performance. The nanocomposites under investigation were either hybrids with a combination of graphene oxide (GO) with multi-walled carbon nanotubes (MWCNTs) or carbon nanofibers (CNFs) at various loadings, or monofillers with varying nanoparticle sizes, at a constant nanofiller loading. In addition, the effect of the type of polymeric matrix on the same nanofiller combinations has been examined. The basic assumption of two phases, namely a matrix with finely dispersed nanoparticles coexisting with agglomerates, was analyzed. The elastic stiffness of the first phase was calculated by the Mori–Tanaka model, and hereafter a semiempirical model was utilized for the estimation of the agglomerates’ stiffness. Within the context of this model, it was shown that the agglomerates’ volume fraction, combined with the nanoparticles’ density, namely the nanoparticles’ volume fraction in the agglomerates and consequently the inclusions’/agglomerates’ enhanced modulus, may cause a substantial improvement in the Young’s modulus, which cannot be explained by conventional mechanical models. These results apply to both nanocomposite types, hybrids at various nanofiller loadings and monofillers with varying particle sizes. Full article

Personalized transdermal drug delivery systems (TDDS) represent a transformative approach in precision medicine by enabling patient-specific, non-invasive, and controlled therapeutic administration. Conventional transdermal patches are limited by fixed dosing, passive diffusion, and interindividual variability in skin permeability and metabolism, often leading to suboptimal therapeutic outcomes. Recent advances in materials science, nanotechnology, microneedle engineering, and digital health have enabled the development of next-generation personalized TDDS capable of programmable, adaptive, and feedback-controlled drug release. Smart wearable patches integrating biosensors, microfluidics, microneedles, and wireless connectivity allow real-time monitoring of physiological and biochemical parameters, enabling closed-loop drug delivery tailored to individual metabolic profiles. Nanocarriers such as lipid nanoparticles, polymeric nanoparticles, and stimuli-responsive hydrogels further enhance drug stability, penetration, and controlled release, while 3D-printing technologies facilitate patient-specific customization of patch geometry, drug loading, and release kinetics. Artificial intelligence (AI) and machine learning tools are increasingly being employed to predict drug permeation behavior, optimize enhancer combinations, and personalize dosing regimens based on pharmacogenomic and pharmacokinetic data. Despite these advances, regulatory complexity, manufacturing standardization, long-term biocompatibility, and cybersecurity considerations remain critical challenges for clinical translation. This review highlights recent innovations in personalized TDDS, discusses their clinical potential, and examines regulatory and technological barriers. Collectively, these emerging smart transdermal platforms offer a promising pathway toward adaptive, patient-centered therapeutics that can significantly improve treatment efficacy, safety, and compliance. Future research should focus on integrating multimodal biosensing, advanced biomaterials, scalable manufacturing strategies, and robust regulatory frameworks to enable clinically validated, fully autonomous transdermal systems that can dynamically adapt to real-time patient needs in diverse therapeutic settings. Full article

Multidrug resistance (MDR) and chemotherapy-associated toxicity remain major challenges limiting the success of cancer treatments. In this context, berberine (BBR), an isoquinoline derivative belonging to the barberry family, has emerged as a promising adjuvant that can enhance the efficacy of chemotherapy while potentially mitigating its side effects. The findings indicate that berberine enhances the therapeutic effect of several drugs, such as doxorubicin, cisplatin, tamoxifen, and 5-fluorouracil, through multiple mechanisms including the inhibition of ABC transporters, regulation of autophagy, and synergistic enhancement of reactive oxygen species generation. Advanced pharmaceutical and nanotechnological formulations, including cyclodextrin complexes, solid dispersions, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, chitosan-based systems, and inorganic nanoplatforms, have demonstrated significant improvements in the solubility, stability, cellular uptake, and oral bioavailability of berberine. However, knowledge gaps remain regarding optimal dosage determination, safety assessment in combination therapy, and establishing efficacy in large-scale clinical trials. Incorporating berberine into combination therapy strategies may improve treatment outcomes, overcome drug resistance, and potentially reduce the toxic burden associated with chemotherapy. Therefore, this review provides a comprehensive analytical framework for berberine’s potential as an adjuvant, elucidates its mechanistic synergistic interactions with standard therapies, explores pharmaceutical strategies to overcome bioavailability limitations, and suggests future research avenues to further its clinical development. Full article

Nanomedicine has advanced rapidly as engineered nanoparticles have become increasingly capable of improving drug stability, targeting, controlled release, and biocompatibility. However, nanoparticle clinical utility relies on both delivery efficiency and how they are metabolized, retained, and cleared. This review examines the major biological pathways governing nanoparticle clearance and discusses how engineering parameters can be tuned to influence bioaccumulation, metabolism, excretion, and therapeutic performance with a wide range of available materials. This article is a narrative review of the recent and foundational literature on medically relevant nanoparticles, including lipid-based, polymeric, biopolymer, inorganic, polylactide, and bile-derived systems. All relevant translational, biochemical, chemical, and clinical literature from PubMed was searched from January 1971 to January 2026 to obtain a representative sample of work before information extraction. Nanoparticle clearance is governed by interconnected molecular and organ-level processes that vary according to composition, size, surface chemistry, and route of administration. Surface modifications with PEGylation, zwitterionic coatings, cholesterol, proteins, or responsive linkers can prolong circulation, alter immune recognition, and direct organ-specific handling. While rapid clearance remains desirable for many systemically acting drugs, prolonged intracellular or intratumoral retention may improve outcomes, particularly in boron neutron capture therapy and other activation-dependent treatments. Nanoparticle clearance should be regarded as a context-dependent design parameter rather than a universal limitation. Rational control of clearance kinetics may improve both safety and therapeutic effectiveness in next-generation engineered drug delivery systems. Full article

Although teixobactin, a promising cyclic undecadepsipeptide, exhibits efficacy against Gram-positive bacteria due to its novel mode of action and low potential for resistance, its clinical application is limited by two key shortcomings: ineffectiveness against Gram-negative bacteria and poor penetration of the protective extracellular polymeric substance (EPS) in biofilms. This renders it unsuitable for targeting the polymicrobial biofilms, which are the cause of periodontitis and peri-implantitis. We designed a modified teixobactin analog by integrating rhamnolipid, Ag@Fe₃O₄ nanoparticles, and _L-Chg₁₀-teixobactin to obtain a novel magnetic nanoparticle (MNP). The MNP demonstrates the ability to simultaneously degrade EPS, penetrate biofilm structures, and eliminate both G⁺ and G^- pathogens under a rotating magnetic field (RMF). Rhamnolipid grafting degraded 52.5% of biofilm EPS. MNPs showed broad-spectrum antimicrobial activity, with minimal inhibitory concentrations from 100 to 200 µg/mL. Combined with RMF, biofilm eradication rates reached 97.0% (E. faecalis), 97.7% (S. gordonii), 88.4% (P. gingivalis), and 74.2% (F. nucleatum). The biofilm thickness was reduced from 19.4 ± 2.9 µm to 7.4 ± 1.0 µm, and the biofilm biomass was reduced by 68.5%. This combined strategy integrates enzymatic EPS degradation, magneto-mechanical disruption, and dual antimicrobial action, offering a promising topical therapy for periodontitis and peri-implantitis. Full article

Cannabinoids (CBs) derived from Cannabis sativa have attracted growing interest for dermatological applications due to their anti-inflammatory, antiproliferative, antimicrobial, antifibrotic, and antipruritic properties. However, their clinical translation is significantly limited by physicochemical and pharmacokinetic challenges, including poor aqueous solubility, lipophilicity, instability, variable skin penetration, and inconsistent bioavailability. At the molecular level, CBs modulate keratinocyte proliferation, sebocyte activity, fibroblast function, melanocyte balance, and immune signalling through CB1/CB2 receptors, TRP channels, and PPARγ pathways. Evidence supports their potential in the treatment of psoriasis, atopic dermatitis, acne, allergic contact dermatitis, pruritus, scleroderma, and skin cancers. Clinical evidence remains preliminary: topical and oral formulations have demonstrated anti-inflammatory, antiproliferative, antibacterial, and antifibrotic effects, with improvements in pruritus, lesion severity, and quality of life in early-phase studies. However, most trials are small, uncontrolled, and lack placebo comparators, limiting generalisability. To overcome formulation barriers and enhance dermal delivery, advanced pharmaceutical strategies such as liposomes, nanoemulsions, polymeric nanoparticles, micelles, and transdermal systems have been investigated to improve stability, controlled release, and targeted skin deposition while minimising systemic exposure. This review integrates mechanistic insights, clinical evidence, and emerging nanotechnology-enabled delivery approaches, emphasising rational formulation design and translational considerations necessary for advancing CBs toward standardised and clinically reliable dermatological therapeutics. Full article

Secondary caries and biofilm accumulation remain major causes of failure in provisional crowns and restorations, highlighting the need for multifunctional resin coatings with antibacterial and remineralizing capabilities. This study aimed to develop a novel bioactive and antibacterial resin-based surface coating incorporating 10% dimethylaminododecyl methacrylate (DMADDM), 20% nanoparticles of amorphous calcium phosphate (NACP), and/or 20% calcium fluoride nanoparticles (nCaF₂) within a urethane dimethacrylate/triethylene glycol divinylbenzyl ether (UDMA/TEG-DVBE) matrix. Coatings were evaluated for degree of conversion (DC), flow, shear bond strength, brushing wear resistance (10,000 cycles), and calcium (Ca), phosphate (PO₄), and fluoride (F) ion release up to 70 days. All groups achieved clinically acceptable polymerization, with the lowest DC at 50%. NACP-containing coatings significantly increased shear bond strength to 18.3 ± 2.8 MPa, representing a ~170% increase compared with the experimental control (6.8 ± 2.1 MPa) and exceeding the ISO 10477 minimum threshold of 5 MPa. After brushing simulation, experimental coatings demonstrated low wear depth (0.93–1.19 µm), which was ~40% lower than the commercial control (1.85 ± 0.40 µm). Sustained ion release was achieved for 70 days, with 20% NACP-formula releasing 1.22 mmol/L Ca and 0.90 mmol/L PO₄, while the dual NACP–nCaF₂ formulation provided simultaneous Ca (0.62 mmol/L) and F (0.33 mmol/L) release. The developed coatings demonstrated promising physicochemical properties, bonding performance, wear resistance, and sustained remineralizing ion release, supporting their potential application as therapeutic surface coatings for provisional restorations. Full article

Chiral polymeric nanoparticles derived from protected L/D-Phe-OMe- and unprotected L/D-Phe-based monomers were developed as functional chiral coatings for PVDF membranes to induce enantioselective recognition. The present study introduced a sonochemichal-assisted approach to the deposition of Phe-based polymeric nanoparticles onto PVDF membranes, generating chiral membrane surfaces that can facilitate enantioselective transport and crystallization. The enantioselective performance of the modified membranes was evaluated through membrane transport experiments using DL-leucine and a crystallization investigation with DL-tyrosine. Enantioselective transport experiments showed pronounced chiral resolution, achieving an enantiomeric excess (ee) of 79/76% for D/L-Leu. Furthermore, enantioselective crystallization was demonstrated using DL-tyrosine in the presence of L/D-Phe-OMe-coated membranes. Optical activity measurements, supported by SEM and DSC analysis, confirm membrane-induced enantiomeric enrichment yielding an ee of 60/68% for L/D-Tyr. These results highlight the potential of chiral polymer-coated PVDF membranes as versatile platforms for enantioselective separation. Full article

Background and Objectives: While nisin exhibits promising antitumor properties, its clinical utility is hindered by pharmacokinetic instability and rapid enzymatic degradation. This systematic review evaluates the critical role of advanced pharmaceutical formulations and targeted nanosystems in overcoming these limitations to enhance nisin’s cytotoxic and pro-apoptotic efficacy in vitro. Methods: Following PRISMA guidelines, a comprehensive search was conducted across six electronic databases (PubMed, ScienceDirect, Scopus, Web of Science, SpringerLink, and DOAJ). In vitro studies comparing free nisin against polymeric, metallic, and cyclodextrin-based nanocarriers across diverse neoplastic lineages were included. Methodological quality was assessed using the SciRAP 2.1 tool, and a within-line comparative analysis was performed for MDA-MB-231 and HT-29 models. Results: Twelve studies met the inclusion criteria. A definitive technological inflection point was identified: nisin-loaded nanosystems reduced effective concentrations by up to 2706-fold relative to the free peptide in MDA-MB-231 cells, and 71-fold in A549 lung cancer cells. Mechanistically, nanosystems facilitated membrane pore formation, mitochondrial-mediated apoptosis via Bax/Bcl-2 modulation, caspase 3/7/9 activation, and p53 reactivation. Three previously underreported mechanistic dimensions were identified: TWIST1 downregulation and FZD7 binding in hepatocellular carcinoma, and downregulation of CEA, CEAM6, MMP2F, and MMP9F in colorectal cancer lines. Conclusions: The therapeutic viability of nisin in oncology is strictly dependent on pharmaceutical engineering. Future research must prioritize in vivo pharmacokinetic validation, experimental confirmation of novel mechanistic targets, and standardized nisin purity reporting to consolidate its clinical translation. Full article

In the pursuit of sustainable and flexible electronics, polymer-based conductive films offer a promising solution due to their biodegradability, mechanical flexibility, and cost-effective fabrication. This study presents the development of a highly conductive and flexible nanocomposite material based on polyaniline-grafted chitosan (PANI-g-Chs) and Vinavil (Vi, a vinyl glue specifically designed for enhancing the sealability of textiles and paper), serving as a matrix for applications in flexible electronics. The PANI-g-Chs nanocomposite was synthesized via in situ oxidative polymerization, where chitosan nanoparticles (Chs) served as a stabilizing template to prevent PANI aggregation, reducing the particle size from 1700 nm (pristine PANI) to 180 nm (PANI-g-Chs). The resulting composite exhibited exceptional electrical conductivity (77.79 S/m at 25 wt% PANI-g-Chs). Hall effect measurements showed that the carrier mobility increased up to 1162.7 cm²/V·s and the carrier density rose to 6.5.1017 cm⁻³, confirming efficient charge transport and network formation. Mechanical analysis revealed a 300% increase in the storage modulus for PANI-g-Chs, and thermal studies confirmed stability up to 300 °C. Optical characterization showed a reduced bandgap (3.6 eV) and extended π-conjugation, which are critical for optoelectronic applications. Application tests demonstrated stable conductivity under mechanical deformation, highlighting the material’s potential for use in flexible electronics, sensors, and sustainable conductive coatings. This work offers a viable alternative to conventional conductive polymers. Full article

Bio-based, biodegradable, and renewable polymers offer a promising alternative to traditional synthetic polymers derived from petroleum or other non-renewable resources. However, their use is limited by suboptimal properties and high costs. Incorporating sustainable reinforcements into the polymer matrix significantly improves biopolymer performance while preserving key properties, sustainability, and cost-effectiveness. Bio-based polymeric composites have emerged as a crucial category of biopolymers, playing a key role in advancing a sustainable, circular economy. This review provides an updated overview of bio-based polymer composites and nanocomposites, focusing on reinforcement strategies using natural nanofillers and engineered nanoparticles. We summarize key synthesis and processing methods, discuss structure–property relationships, and highlight recent advances in applications such as food packaging, biomedical devices, energy systems, environmental remediation, 3D printing, and supercapacitors. Polymer nanocomposites are versatile, with their performance depending on the type, size, and interactions between the fillers and the polymer matrix. Progress in metallic, ceramic, carbon-based, natural, and hybrid fillers has improved their properties. Using bio-based polymers and renewable fillers supports sustainability. Natural nanofillers derived from renewable sources and industrial byproducts offer a sustainable approach to developing high-performance, biodegradable nanocomposites. Smart nanocomposites can react to external stimuli by integrating specialized fillers that enhance their mechanical and mobility properties. Shape memory nanocomposites can be remotely activated—using heat, electricity, magnets, or light—enabling advanced applications. Finally, we address major challenges and outline future directions for scalable, circular-material solutions, drawing on perspectives from the circular economy and life cycle assessment (LCA). Full article

Phytochemicals have attracted considerable attention as therapeutically relevant bioactive compounds due to their diverse pharmacological activities, including anti-inflammatory, antioxidant, anticancer, and metabolic regulatory effects. However, their clinical translation is frequently hindered by unfavorable pharmaceutical properties such as poor aqueous solubility, chemical instability, rapid metabolism, and limited bioavailability. These challenges have constrained the reproducibility and therapeutic reliability of phytochemical-based interventions. In this context, nanotechnology-enabled delivery systems have emerged as effective strategies to overcome the intrinsic limitations of phytochemicals and enhance their biological performance. This review provides a comprehensive overview of recent advances in nanotechnology-based delivery platforms for phytochemicals, with emphasis on lipid-based nanocarriers, polymeric nanoparticles, nanoemulsions and self-nanoemulsifying drug delivery systems, inorganic and hybrid nanocarriers, as well as hydrogel-based and transdermal delivery systems. We discuss how rational nanocarrier design improves solubility, stability, pharmacokinetics, cellular uptake, and tissue targeting, thereby enhancing therapeutic efficacy across multiple disease areas. In addition, critical safety, toxicity, manufacturing, and regulatory considerations that influence translational potential are addressed. By adopting a delivery-centered perspective, this review highlights current challenges and future opportunities in nano-phytomedicine and underscores the importance of integrating nanotechnology, biological insight, and regulatory-conscious development to advance phytochemicals toward clinically viable therapeutic applications. Full article

Printed electronics have emerged as a versatile manufacturing platform for next-generation biosensors, enabling on-demand and low-cost fabrication of functional devices on flexible, stretchable, and unconventional substrates. One major challenge in this field lies in the sintering of printed features, as conventional high-temperature processing is incompatible with polymeric substrates and thermally sensitive biological components. Low-temperature sintering inks, typically processed below 200 °C or even at room temperature, have become a critical enabling technology for bio-integrated electronics. This review provides an overview of the current state-of-the-art and key challenges associated with low-temperature sintering inks for printed bioelectronics. We discuss inks based on metal nanoparticles, metal–organic decomposition precursors, metal oxides, chalcogenides, and hybrid material systems. The emphasis is on how ink chemistry, ligand selection, and precursor structure govern rheology, stability, and sintering behavior. In addition, key low-temperature sintering and curing strategies, including thermal, photonic, laser, plasma, microwave, and chemical sintering, are compared in terms of energy delivery, densification mechanisms, and substrate compatibility. Finally, we outline emerging directions towards low temperature and room-temperature sintering inks, and sustainable biobased ink formulations, and discuss their applications for wearable, implantable, and soft biosensing platforms. Full article

Background/Objectives: Oral diseases remain among the most prevalent noncommunicable conditions worldwide, with biofilm-driven dysbiosis playing a central role in dental caries, gingivitis, periodontitis, and oral candidiasis. Curcumin has attracted considerable interest because of its anti-inflammatory, antioxidant, antimicrobial, and regenerative properties. However, its clinical use remains limited by poor water solubility, chemical instability, rapid metabolism, and low bioavailability. This review aimed to provide a comprehensive analysis of curcumin-based nanoformulations for oral health applications, with emphasis on their mechanistic actions, antibiofilm activity, and translational relevance. Methods: This review examined representative nanocarrier systems developed for curcumin delivery in oral health. These included polymeric nanoparticles, nanomicelles and nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers, nanogels, hydrogels, mucoadhesive films, and metallic or hybrid nanosystems. The analysis focused on molecular mechanisms of action, antimicrobial and antibiofilm effects against major oral pathogens, and key translational challenges. Results/Findings: Across the reviewed studies, nanoformulations consistently improved curcumin solubility, stability, tissue penetration, mucosal retention, and controlled release. Mechanistically, they enhanced anti-inflammatory activity through inhibition of nuclear factor kappa B (NF-κB), strengthened antioxidant defenses via the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) axis, supported tissue repair and osteogenic responses, disrupted oral biofilms, and modulated local immune responses. Antimicrobial activity was reported against Streptococcus mutans, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Candida albicans, with reduced exopolysaccharide production, impaired adhesion, and improved biofilm penetration. Conclusions: Curcumin-based nanoformulations represent promising adjunctive platforms for oral healthcare. However, their clinical translation still requires improved stability in the oral-environment standardized manufacturing and characterization, rigorous safety evaluation, and well-designed controlled clinical studies. Full article